- Blood and genomic testing are becoming preferable means of early cancer screening and detection
- Leaders innovating this niche of the medical industry include AnPac Bio, Grail, Thrive and Guardant
- AnPac Bio-Medical’s testing features a database of more than 200,000 commercial and research multi-cancer test samples (probably the largest multi-cancer test data base) that detect up to 26 different types of cancer
- One of the few companies offering multi-cancer tests for risk assessment and actually contributing to the fight against cancer by having its high risk individuals (tested first by its tests and later) confirmed in the healthcare providers for cancer patients and pre-cancer patients early
Almost 1.9 million new cancer cases will be diagnosed in the United States in 2021, according to American Cancer Society (“ACS”) estimates. This number excludes basal cell, squamous cell skin cancer, and carcinoma in situ except for urinary bladder cancer. The ACS also estimates that the number of Americans to die from cancer in 2021 will be 608,570, equivalent to 1,670 people per day (https://ibn.fm/qcO5q). To address these rising cancer rates, biotechnology companies in the U.S. and worldwide are focusing on the early detection and screening of cancer through the development of proprietary technologies.
AnPac Bio-Medical Science
The companies currently paving the way for early cancer screening and detection include AnPac Bio-Medical Science (NASDAQ: ANPC), Illumina, Inc.’s (NASDAQ: ILMN), Grail, Inc. (now part of Illumina), Exact Sciences Co., Ltd. (NASDAQ: EXAS), and Thrive Earlier Detection (now part of Exact Sciences), and Guardant Health (NASDAQ: GH). All four of these companies have developed blood and genomic tests that help detect and screen for early cancers, some of which have no other means of early detection.
Powered by a database containing over 200,000 samples and cases, AnPac Bio’s Cancer Differentiation Analysis (“CDA”) is a proprietary novel technology for early cancer screening and detection. CDA technology can detect and carry multi-level information including cellular and protein level information to determine the existence of cancerous environments. At present, our CDA platform can detect up to 26 different types of cancer, which gives AnPac Bio a major advantage over industry peers in terms of cost effectiveness, multi-cancer testing, ability to detect cancer early with high sensitivity and specificity.
With its proprietary technology and being one of the first companies in the world to introduce the concept of multi-level, multi-parameter and multi-cancer (pan-cancer) screening approaches, AnPac Bio is uniquely positioned to be a leader among other prominent cancer screening and detection blood testing companies currently on the market. The company has accredited clinical laboratories in the U.S. and China, and a total of 142 patents issued since the early 2010s, a significantly higher number of patents as compared to its industry peers (Grail has 80 patents https://ibn.fm/iQ09Q and Thrive has 1 filed patent https://ibn.fm/LOBXP). In 2019, a Frost & Sullivan report ranked AnPac Bio third in the world and first in China among those companies that offer next-generation early cancer screening and detection testing in terms of the number of clinical samples.
Other Companies
Thrive’s CancerSeek is a liquid biopsy blood test for the detection of cancer at its early stages. The results were published in a 2020 issue of Science, demonstrating that the blood test more than doubled the number of detected cancers, with 65% of these samples were at earlier stages, across ten cancer types, with seven of them having no recommended standard-of-care tests.
Guardant Health reported recently at ASCO 2021 that its Lunar-2 colorectal cancer screening study achieved overall sensitivity of 91% in early-stage CRC detection (stage I, II, and III), and specificity of 94%. The ECLIPSE study will screen for colorectal cancer where they plan to enroll 10,000 people between the ages of 60-84 from across the United States by the end of 2021.
Galleri(TM) is GRAIL’s trademarked cancer screening and detection blood test. This blood test can detect over 50 types of cancer, allowing patients to take control of their health and be proactive about cancer screening. This blood test is recommended for people ages 50 and older and is intended to be used in addition to other cancer screening tools recommended by a primary healthcare provider.
Liquid biopsy-based noninvasive testing is leading the way for early cancer screening, detection and diagnosis, often preferable to other cancer testing methods. With an increase in cancer cases globally, early detection and screening is becoming prevalent across much of the healthcare industry. Worldwide, the cancer diagnostics market is expected to grow at a CAGR of 7% during the forecast period, resulting in a market value of $249.6 billion by 2026 (https://ibn.fm/aANDy).
For more information, visit the company’s website at www.AnPacBio.com.
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
